There is now a greater understanding of the molecular pathways in ovarian cancer, and
using this knowledge, a large number of new therapeutic agents can be tested. The success …

The standard regimen used as primary chemotherapy of ovarian cancer is combination
chemotherapy using paclitaxel and carboplatin. The main objective of first-line …

Although significant success has been achieved in the treatment of advanced and recurrent
ovarian cancer, there is clearly room for improvement. The use of targeted agents in this …

Introduction: Epithelial ovarian cancer is the most lethal gynecologic malignancy. Recent
advances in understanding the biology and its molecular and histological diversity have led …

The gold standard chemotherapy for previously untreated patients with ovarian cancer is
currently a combination of taxane and platinum. However, most patients still suffer relapse …

Much further research is required to define if, when and how best to integrate these novel
therapies, and also to define associated biomarkers that predict toxicity and select patients …

Ovarian cancer is an important health concern worldwide. The majority of patients present
with advanced disease, and despite initial chemosensitivity, most relapse and die from their …

AIMS: Epithelial ovarian cancer is responsible for 4% of all cancer deaths in women, and the
five-year overall survival of patients with advanced disease is 30–40%. Treatment currently …

Unfortunately, ovarian cancer is still diagnosed most often only in an advanced stage and is
also the most lethal gynecological cancer. Another problem is the fact that treated patients …

Molecularly targeted therapy is relatively new to ovarian cancer despite the unquestionable
success with these agents in other solid tumours such as breast and colorectal cancer …